CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States

Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Dr. William Garrett Nichols M.D., MSChief Medical Officer493.88kN/A1969
Mr. Michael A. ShermanCEO, Pres & DirectorN/AN/A1966
Mr. Michael T. AndrioleChief Bus. Officer & CFON/AN/A1973
Mr. David JakemanExec. Director of Fin. & Accounting and Principal Accounting OfficerN/AN/A1977
Dr. Roy W. Ware Ph.D., MBAChief Manufacturing & Technology OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. Chimerix, Inc. has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; and Cantex Pharmaceuticals, Inc. for the development and commercialization of CX-01, a heparin derivative that is used in the treatment of acute myeloid leukemia and other serious diseases. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.